Rallybio (RLYB) Stock Price, News & Analysis

Company Overview

Rallybio Corporation (NASDAQ:RLYB) is a clinical-stage biotechnology company focused on developing therapies for rare diseases and conditions with significant unmet medical needs. The company seeks to address disorders in which relatively small patient populations may face limited treatment options.

Rallybio’s pipeline has included RLYB212, an investigational antibody designed to prevent fetal and neonatal alloimmune thrombocytopenia, a potentially serious condition that can occur when maternal antibodies attack fetal platelets. The company has also pursued early-stage programs involving complement biology and other disease mechanisms.

Rallybio was founded in 2018 and is based in New Haven, Connecticut. Its development activities are primarily focused on advancing drug candidates through clinical and preclinical research, with the goal of potentially serving patients in the United States and international markets if its therapies receive regulatory approval.

Key Stats

• Today's Range: $16.61 to $17.19
• 50-Day Range: $15.93 to $17.22
• 52-Week Range: $3.67 to $17.57
• Volume: 6,496 shs
• Average Volume: 135,328 shs
• Market Capitalization: $89.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Rallybio Stock Analysis - MarketRank™

Rallybio scored higher than 9% of companies evaluated by MarketBeat, and ranked 873rd out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Rallybio has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Rallybio has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Rallybio is -3.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rallybio is -3.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Rallybio has a P/B Ratio of 1.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

1.17% of the float of Rallybio has been sold short.

Short Interest Ratio / Days to Cover

Rallybio has a short interest ratio ("days to cover") of 5.04.

Change versus previous month

Short interest in Rallybio has recently increased by 1.12%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rallybio does not currently pay a dividend.

Dividend Growth

Rallybio does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

Rallybio has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Rallybio this week, compared to 1 article on an average week.

MarketBeat Follows

3 people have added Rallybio to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Rallybio insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.30% of the stock of Rallybio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

90.34% of the stock of Rallybio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/29/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:RLYB
• CIK: 1739410
• Web: www.rallybio.com
• Phone: (203) 859-3820
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($4.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.98 million
• Net Margins: -911.07%
• Pretax Margin: 7,256.19%
• Return on Equity: -40.53%
• Return on Assets: -38.13%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 27.26
• Quick Ratio: 27.26

Sales & Book Value

• Annual Sales: $860 thousand
• Price / Sales: 104.82
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.98 per share
• Price / Book: 1.55

Miscellaneous

• Outstanding Shares: 5,310,000
• Free Float: 4,764,000
• Market Cap: $90.14 million
• Optionable: Not Optionable
• Beta: -0.85